Molly Purser, PhD

Director of Global Real-world Evidence & Health Outcomes
GSK

Poster(s):

• (306) Life-year and quality-adjusted life-year results from a United States cost-effectiveness model for belantamab mafodotin, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma
  Wednesday, October 29, 2025

• (311) Belantamab Mafodotin Individual Patient Dosing in Patients With Relapsed/Refractory Multiple Myeloma Treated in the Phase 3 DREAMM-7 and DREAMM-8 Clinical Trials
  Wednesday, October 29, 2025

• (332) Burden of Administration: Belantamab Mafodotin (Belamaf) Combinations vs Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d), Daratumumab (D) + K + d, and K + d in Relapsed/Refractory Multiple Myeloma (RRMM)
  Wednesday, October 29, 2025